EU/3/20/2331: Orphan designation for the treatment of multiple myeloma

Teclistamab

Overview

Please note that this product was withdrawn from the Union Register of orphan medicinal products in July 2022 on request of the Sponsor.

On 19 October 2020, orphan designation EU/3/20/2331 was granted by the European Commission to Janssen-Cilag International N.V, Belgium, for teclistamab for the treatment of multiple myeloma.

Key facts

Active substance
Teclistamab
Intended use
Treatment of multiple myeloma
Orphan designation status
Withdrawn
EU designation number
EU/3/20/2331
Date of designation
19/07/2022
Sponsor

Turnhoutseweg 30
2340 Beerse Antwerp
Belgium
Tel: +353857446696
E-mail: nbuhl@its.jnj.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating